Meng Yiling, Zhou Jiawei, Liu Xuanxin, Zeng Fei, Wen Tao, Meng Jie, Liu Jian, Xu Haiyan
Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Peking Union Medical College, Beijing 100005, China.
Peking Union Medical College Hospital, Beijing 100730, China.
ACS Appl Mater Interfaces. 2023 Apr 19;15(15):18734-18746. doi: 10.1021/acsami.3c03130. Epub 2023 Apr 5.
Triple-negative breast cancer (TNBC) is highly challenging in its treatment because of the lack of the targeted markers. TNBC patients are not able to acquire benefits from endocrine therapy and targeted therapy except for chemotherapy. CXCR4 is highly expressed on TNBC cells that mediated the tumor cell metastasis as well as proliferation by the response of its ligand CXCL12, therefore holding promising potential of a candidate target for the treatment. In this work, a novel conjugate of CXCR4 antagonist peptide E5 and gold nanorods was fabricated (AuNRs-E5), which was applied to murine breast cancer tumor cells and an animal model, aiming to induce endoplasmic reticulum stress by endoplasmic reticulum-targeted photothermal immunological effects. Results showed that AuNRs-E5 could induce much more generation of damage-related molecular patterns in 4T1 cells under laser irradiation than AuNRs, which significantly promoted the maturation of dendritic cells and stimulated systematic anti-tumor immune responses by enhancing the infiltration of CD8T cells into the tumor and tumor-draining lymph node, downregulating the regulatory T lymphocytes, and upregulating M1 macrophages in tumors, reversing the microenvironment from "cold" tumors to "hot" tumors. The administration of AuNRs-E5 with laser irradiation not only inhibited the tumor growth significantly but also exerted specific long immune responses to the triple-negative breast cancer tumor cells, which led to the prolonged survival of the mice and the specific immunological memory.
三阴性乳腺癌(TNBC)因其缺乏靶向标志物,在治疗上极具挑战性。除化疗外,TNBC患者无法从内分泌治疗和靶向治疗中获益。CXCR4在TNBC细胞上高表达,其通过配体CXCL12的反应介导肿瘤细胞转移和增殖,因此具有作为治疗候选靶点的巨大潜力。在这项工作中,制备了一种新型的CXCR4拮抗剂肽E5与金纳米棒的缀合物(AuNRs-E5),并将其应用于小鼠乳腺癌肿瘤细胞和动物模型,旨在通过内质网靶向光热免疫效应诱导内质网应激。结果表明,在激光照射下,AuNRs-E5比金纳米棒能在4T1细胞中诱导更多损伤相关分子模式的产生,这显著促进了树突状细胞的成熟,并通过增强CD8T细胞向肿瘤和肿瘤引流淋巴结的浸润、下调调节性T淋巴细胞以及上调肿瘤中的M1巨噬细胞,刺激全身性抗肿瘤免疫反应,将微环境从“冷”肿瘤转变为“热”肿瘤。AuNRs-E5与激光照射联合应用不仅显著抑制了肿瘤生长,还对三阴性乳腺癌肿瘤细胞产生了特异性的长期免疫反应,从而延长了小鼠的生存期并产生了特异性免疫记忆。